2SLATTERY J T,CLIFT R A,BUCKNER C D,et al.Marrow teansplantation for chronic myeloid leukemia:the influence of plasma busulfan levels on the outcome of transplantion[J].Blood,1997,89:3055-3060.
3GROCHOW L B,JONES R J,BRUNDET R B,et al.Pharmacokinetics of busulfan:correlation with veno-occlusive disease in patients under going bone marrow transplantation[J].Cancer Chemother Pharmacol,1989,25:55.
4陈灏珠.使用内科学[M].上海:人民卫生出版社,2001:1620.
二级参考文献4
1Slattery J-T,Cliff RA,Buekner CD,et al.Marrow transplantation for chronic myeloid leukemia:the influence of plasma busulfan levels on the outcome of transplantation.Blood,1997,89:3055-3060.
2Groehow LB,Jones RJ,Branded RB,et al.Pharmacokinetics of busulfan:correlation with veno-ocelusive disease in patients undergoing bone marrow transplantation.Cancer Chemother Pharmacol,1989,25:55.
3Merease V,Hartmann O,Vassal G,et al.Risk factors for hepatic veno-occlusive disease after high-dose,busulfan-containing regimens followed by autologous bone marrow transplantation:a study in 136 children.Bone Marrow Transplant,1992,10:135.
4Bearman SI,Appelbaum FR,Buekner CD,et al.Regimen related toxicity in patients undergoing bone marrow transplantationj Clin Oncol,1988,6(10):1562-1568.
3PORTER M, PENNEY G C, RUSSELL D, et al. A population based survey of women's experience of the menopause [ J ]. Br J Onsted Gunaccol, 1996,103 (10) : 1025 - 1028.
4潘孟昭.护理学导论[M].人民卫生出版社,2003:49.
5GUO MEI,HU KAI - XUN, YU CHANG - LIN, et al. Infusion of HLA - mismatched peripheral blood stem cells improves the out- come of chemotherapy for acute myeloid leukemia in elderly pa- tients [ J ]. BLOOD,2011,117 (3) :936 - 941.
